These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 22628060)

  • 1. Edoxaban administration following enoxaparin: a pharmacodynamic, pharmacokinetic, and tolerability assessment in human subjects.
    Zahir H; Matsushima N; Halim AB; He L; Zhang G; Lee F; Worland V; Mendell J
    Thromb Haemost; 2012 Jul; 108(1):166-75. PubMed ID: 22628060
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficacy of edoxaban, an oral factor Xa inhibitor, versus enoxaparin for thromboprophylaxis after total knee arthroplasty: the STARS E-3 trial.
    Fuji T; Wang CJ; Fujita S; Kawai Y; Nakamura M; Kimura T; Ibusuki K; Ushida H; Abe K; Tachibana S
    Thromb Res; 2014 Dec; 134(6):1198-204. PubMed ID: 25294589
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and efficacy of edoxaban in patients undergoing hip fracture surgery.
    Fuji T; Fujita S; Kawai Y; Nakamura M; Kimura T; Kiuchi Y; Abe K; Tachibana S
    Thromb Res; 2014 Jun; 133(6):1016-22. PubMed ID: 24680549
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of venous thrombosis with an oral direct factor Xa inhibitor edoxaban by single and multiple administrations in rats.
    Morishima Y; Kamisato C; Honda Y
    Eur J Pharmacol; 2014 Nov; 742():15-21. PubMed ID: 25179572
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of a direct Factor Xa inhibitor, edoxaban, with dalteparin and ximelagatran: a randomised controlled trial in healthy elderly adults.
    Samama MM; Kunitada S; Oursin A; Depasse F; Heptinstall S
    Thromb Res; 2010 Oct; 126(4):e286-93. PubMed ID: 20807664
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of edoxaban on markers of coagulation in venous and shed blood compared with fondaparinux.
    Wolzt M; Samama MM; Kapiotis S; Ogata K; Mendell J; Kunitada S
    Thromb Haemost; 2011 Jun; 105(6):1080-90. PubMed ID: 21544313
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Edoxaban in the prevention and treatment of thromboembolic complications from a clinical point of view.
    Barrios V; Escobar C
    Expert Rev Cardiovasc Ther; 2015; 13(7):811-24. PubMed ID: 26068539
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of antithrombotic and haemorrhagic effects of edoxaban, an oral direct factor Xa inhibitor, with warfarin and enoxaparin in rats.
    Morishima Y; Honda Y; Kamisato C; Tsuji N; Kita A; Edo N; Shibano T
    Thromb Res; 2012 Sep; 130(3):514-9. PubMed ID: 22647432
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Determination of edoxaban equivalent concentrations in human plasma by an automated anti-factor Xa chromogenic assay.
    He L; Kochan J; Lin M; Vandell A; Brown K; Depasse F
    Thromb Res; 2017 Jul; 155():121-127. PubMed ID: 28535438
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro study of the anticoagulant effects of edoxaban and its effect on thrombin generation in comparison to fondaparinux.
    Samama MM; Mendell J; Guinet C; Le Flem L; Kunitada S
    Thromb Res; 2012 Apr; 129(4):e77-82. PubMed ID: 21851967
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics, safety, and tolerability of edoxaban in end-stage renal disease subjects undergoing haemodialysis.
    Parasrampuria DA; Marbury T; Matsushima N; Chen S; Wickremasingha PK; He L; Dishy V; Brown KS
    Thromb Haemost; 2015 Apr; 113(4):719-27. PubMed ID: 25566930
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effects of the antiplatelet agents, aspirin and naproxen, on pharmacokinetics and pharmacodynamics of the anticoagulant edoxaban, a direct factor Xa inhibitor.
    Mendell J; Lee F; Chen S; Worland V; Shi M; Samama MM
    J Cardiovasc Pharmacol; 2013 Aug; 62(2):212-21. PubMed ID: 23615159
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Edoxaban for the long-term treatment of venous thromboembolism: rationale and design of the Hokusai-venous thromboembolism study--methodological implications for clinical trials.
    Raskob G; Büller H; Prins M; Segers A; Shi M; Schwocho L; van Kranen R; Mercuri M;
    J Thromb Haemost; 2013 Jul; 11(7):1287-94. PubMed ID: 23574579
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized trial of the safety, pharmacokinetics and pharmacodynamics of edoxaban, an oral factor Xa inhibitor, following a switch from warfarin.
    Mendell J; Noveck RJ; Shi M
    Br J Clin Pharmacol; 2013 Apr; 75(4):966-78. PubMed ID: 22924409
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Efficacy and Safety of Edoxaban for VTE Prophylaxis Post-Orthopedic Surgery: A Systematic Review.
    AlHajri L; Jabbari S; AlEmad H; AlMahri K; AlMahri M; AlKitbi N
    J Cardiovasc Pharmacol Ther; 2017 May; 22(3):230-238. PubMed ID: 27811198
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral direct factor Xa inhibition with edoxaban for thromboprophylaxis after elective total hip replacement. A randomised double-blind dose-response study.
    Raskob G; Cohen AT; Eriksson BI; Puskas D; Shi M; Bocanegra T; Weitz JI
    Thromb Haemost; 2010 Sep; 104(3):642-9. PubMed ID: 20589317
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of the direct factor Xa inhibitor edoxaban and digoxin administered alone and in combination.
    Mendell J; Noveck RJ; Shi M
    J Cardiovasc Pharmacol; 2012 Oct; 60(4):335-41. PubMed ID: 23064240
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of edoxaban, an oral factor xa inhibitor, for thromboprophylaxis after total hip arthroplasty in Japan and Taiwan.
    Fuji T; Wang CJ; Fujita S; Kawai Y; Kimura T; Tachibana S
    J Arthroplasty; 2014 Dec; 29(12):2439-46. PubMed ID: 25047458
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dose reduction of edoxaban preserves efficacy and safety for the treatment of venous thromboembolism. An analysis of the randomised, double-blind HOKUSAI VTE trial.
    Verhamme P; Wells PS; Segers A; Ageno W; Brekelmans MP; Cohen AT; Meyer G; Grosso MA; Raskob G; Weitz JI; Zhang G; Buller H
    Thromb Haemost; 2016 Sep; 116(4):747-53. PubMed ID: 27440518
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thrombin generation induced by tissue factor plus ADP in human platelet rich plasma: A potential new measurement to assess the effect of the concomitant use of an oral factor Xa inhibitor edoxaban and P2Y12 receptor antagonists.
    Honda Y; Morishima Y
    Thromb Res; 2015 May; 135(5):958-62. PubMed ID: 25791908
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.